Elsevier

Radiotherapy and Oncology

Volume 154, January 2021, Page e17
Radiotherapy and Oncology

COVID-19 Rapid Letter
Response to, “Role of neoadjuvant radiochemotherapy for esophageal cancers over pre/peri-operative chemotherapy in the era of COVID-19 and beyond”

https://doi.org/10.1016/j.radonc.2020.07.011Get rights and content

Cited by (0)

The Editors of the Journal, the Publisher and the European Society for Radiotherapy and Oncology (ESTRO) cannot take responsibility for the statements or opinions expressed by the authors of these articles. Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds or experiments described herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. For more information see the editorial “Radiotherapy & Oncology during the COVID-19 pandemic”, Vol. 146, 2020.

View Abstract